2seventy bio, Inc.

NasdaqGS:TSVT Stock Report

Market Cap: US$258.6m

2seventy bio Valuation

Is TSVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TSVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TSVT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TSVT's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TSVT?

Other financial metrics that can be useful for relative valuation.

TSVT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.9x
Enterprise Value/EBITDA-1.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TSVT's PS Ratio compare to its peers?

The above table shows the PS ratio for TSVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
PBYI Puma Biotechnology
1.1x-0.1%US$254.1m
VNDA Vanda Pharmaceuticals
1.2x9.6%US$237.1m
AKBA Akebia Therapeutics
1.6x17.9%US$305.7m
ACIU AC Immune
15.9x41.4%US$257.4m
TSVT 2seventy bio
2.6x8.8%US$258.6m

Price-To-Sales vs Peers: TSVT is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (4.9x).


Price to Earnings Ratio vs Industry

How does TSVT's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: TSVT is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Biotechs industry average (13.2x).


Price to Sales Ratio vs Fair Ratio

What is TSVT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TSVT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: TSVT is good value based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TSVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.04
US$10.50
+108.3%
65.9%US$25.00US$5.00n/a6
Apr ’25US$5.79
US$10.50
+81.3%
65.9%US$25.00US$5.00n/a6
Mar ’25US$5.64
US$11.00
+95.0%
60.0%US$20.00US$5.00n/a5
Feb ’25US$5.19
US$10.67
+105.5%
56.9%US$20.00US$5.00n/a6
Jan ’25US$4.27
US$8.00
+87.4%
72.2%US$20.00US$2.00n/a6
Dec ’24US$1.94
US$9.00
+363.9%
67.0%US$20.00US$2.00n/a6
Nov ’24US$2.33
US$12.17
+422.2%
63.4%US$28.00US$5.00n/a6
Oct ’24US$3.92
US$18.00
+359.2%
59.2%US$33.00US$5.00n/a5
Sep ’24US$5.17
US$24.33
+370.7%
25.2%US$33.00US$13.00n/a6
Aug ’24US$6.94
US$25.00
+260.2%
25.0%US$33.00US$13.00n/a6
Jul ’24US$10.12
US$28.17
+178.3%
8.0%US$33.00US$26.00n/a6
Jun ’24US$12.08
US$28.17
+133.2%
8.0%US$33.00US$26.00n/a6
May ’24US$10.30
US$27.83
+170.2%
9.6%US$33.00US$24.00n/a6
Apr ’24US$10.20
US$27.50
+169.6%
12.7%US$33.00US$21.00US$5.796
Mar ’24US$11.01
US$28.83
+161.9%
8.1%US$34.00US$27.00US$5.646
Feb ’24US$13.20
US$28.83
+118.4%
8.1%US$34.00US$27.00US$5.196
Jan ’24US$9.37
US$29.17
+211.3%
19.1%US$41.00US$24.00US$4.276
Dec ’23US$15.28
US$30.17
+97.4%
16.8%US$41.00US$25.00US$1.946
Nov ’23US$15.79
US$30.00
+90.0%
18.6%US$42.00US$25.00US$2.336
Oct ’23US$14.55
US$29.80
+104.8%
20.7%US$42.00US$25.00US$3.925
Sep ’23US$15.45
US$29.80
+92.9%
20.7%US$42.00US$25.00US$5.175
Aug ’23US$14.30
US$32.60
+128.0%
23.9%US$42.00US$24.00US$6.945
Jul ’23US$13.34
US$33.20
+148.9%
22.7%US$42.00US$24.00US$10.125
Jun ’23US$11.85
US$33.20
+180.2%
22.7%US$42.00US$24.00US$12.085
May ’23US$13.46
US$36.75
+173.0%
16.7%US$42.00US$27.00US$10.304
Apr ’23US$18.17
US$36.75
+102.3%
16.7%US$42.00US$27.00US$10.204

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.